Immune-competent human skin disease models

Drug Discovery Today

Volumn 21, Issue 9, 2016, Pages 1479-1488

  Bergers, Lambert I J C ^a   Reijnders, Christianne M A ^a   van den Broek, Lenie J ^a   Spiekstra, Sander W ^a   de Gruijl, Tanja D ^a   Weijers, Ester M ^a   Gibbs, Susan ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY; SKIN DISEASE;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; SKIN DISEASES;

EID: 84988329134     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.05.008     Document Type: Review

References (118)

1. 1 Pasparakis, M., et al. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14 (2014), 289–301.
2. 2 GlaxoSmithKlein, The Investigational MAGE A3 Antigen Specific Cancer Immunotherapeutic Does Not Meet First co Primary Endpoint in Phase III Melanoma Clinical Trial. 2013 Available at: https://www.gsk.com/en-gb/media/press-releases/2013/the-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoint-in-phase-iii-melanoma-clinical-trial/.
3. 3 Mak, I.W., et al. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6 (2014), 114–118.
4. 4 Seok, J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3507–3512.
5. 5 Shultz, L.D., et al. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7 (2007), 118–130.
6. 6 Kenney, L.L., et al. Humanized mouse models for transplant immunology. Am. J. Transplant. 16 (2016), 389–397.
7. 7 Akkina, R., et al. Improvements and limitations of humanized mouse models for HIV research: NIH/NIAID “Meet the Experts” 2015 Workshop Summary. AIDS Res. Hum. Retroviruses 32 (2016), 109–119.
8. 8 DiMasi, J.A., et al. Cost of developing a new drug innovation in the pharmaceutical industry. 2014 Available at: http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014.pdf.
9. 9 Hay, M., et al. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (2014), 40–51.
10. 10 Cosmetics Europe, European Union Cosmetics Directive 76/768/EEC. 2004 Available at: https://www.cosmeticseurope.eu/publications-cosmetics-europe-association/european-union-cosmetics-directives.html?view=item&id=14.
11. 11 Leist, M., et al. Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31 (2014), 341–356.
12. 12 van den Broek, L.J., et al. Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective. Exp. Dermatol. 23 (2014), 382–386.
13. 13 Nestle, F.O., et al. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9 (2009), 679–691.
14. 14 Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969.
15. 15 Chia, J.J., Lu, T.T., Update on macrophages and innate immunity in scleroderma. Curr. Opin. Rheumatol. 27 (2015), 530–536.
16. 16 Zhu, Z., et al. The natural behavior of mononuclear phagocytes in HTS formation. Wound Repair Regen. 24 (2015), 14–25.
17. 17 Braga, T.T., et al. Macrophages during the fibrotic process: M2 as friend and foe. Front. Immunol., 6, 2015, 602.
18. 18 Wong, V.W., et al. Mechanical force prolongs acute inflammation via T-cell-dependent pathways during scar formation. FASEB J. 25 (2011), 4498–4510.
19. 19 Van Den Broek, L.J., et al. Development, validation, and testing of a human tissue engineered hypertrophic scar model. ALTEX 29 (2012), 389–402.
20. 20 Murao, N., et al. Treg-enriched CD4+ T cells attenuate collagen synthesis in keloid fibroblasts. Exp. Dermatol. 23 (2014), 266–271.
21. 21 Asano, Y., Recent advances in animal models of systemic sclerosis. J. Dermatol. 43 (2016), 19–28.
22. 22 Noda, S., et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat. Commun., 5, 2014, 5797.
23. 23 Ayano, M., et al. Increased CD226 expression on CD8+ T cells is associated with upregulated cytokine production and endothelial cell injury in patients with systemic sclerosis. J. Immunol. 195 (2015), 892–900.
24. 24 Cipriani, P., et al. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin. Exp. Immunol. 173 (2013), 195–206.
25. 25 Ezzedine, K., et al. Vitiligo. Lancet 386 (2015), 74–84.
26. 26 Richmond, J.M., et al. Innate immune mechanisms in vitiligo: danger from within. Curr. Opin. Immunol. 25 (2013), 676–682.
27. 27 Taieb, A., Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 25 (2012), 9–13.
28. 28 Dwivedi, M., et al. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics. Autoimmun. Rev. 14 (2015), 49–56.
29. 29 van den Boorn, J.G., et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129 (2009), 2220–2232.
30. 30 Ouwehand, K., et al. Technical advance: Langerhans cells derived from a human cell line in a full-thickness skin equivalent undergo allergen-induced maturation and migration. J. Leukoc. Biol. 90 (2011), 1027–1033.
31. 31 Cario-Andre, M., et al. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis. Pigment Cell Res. 20 (2007), 385–393.
32. 32 MatTek Corporation, USA. Pigmented, Melanoma and Psoriasis Tissue Models. Available at: https://www.mattek.com/product-category/tissue-models/.
33. 33 Stalder, J.F., et al. Fragility of epidermis and its consequence in dermatology. J. Eur. Acad. Dermatol. Venereol. 28:Suppl. 4 (2014), 1–18.
34. 34 Gupta, R., et al. Epidermolysis bullosa acquisita. Clin. Dermatol. 30 (2012), 60–69.
35. 35 Esposito, S., et al. Epidermolysis bullosa and the partnership with autoimmunity: what should we assimilate?. Immunol. Res. 61 (2015), 63–69.
36. 36 Vassileva, S., et al. Autoimmune blistering dermatoses as systemic diseases. Clin. Dermatol. 32 (2014), 364–375.
37. 37 Jiang, Q.J., Uitto, J., Animal models of epidermolysis bullosa—targets for gene therapy. J. Invest. Dermatol., 124, 2005 xi–xiii.
38. 38 Bieber, K., et al. Animal models for autoimmune bullous dermatoses. Exp. Dermatol. 19 (2010), 2–11.
39. 39 Sitaru, C., Experimental models of epidermolysis bullosa acquisita. Exp. Dermatol. 16 (2007), 520–531.
40. 40 Woodley, D.T., Chen, M., Recessive dystrophic epidermolysis bullosa: advances in the laboratory leading to new therapies. J. Invest. Dermatol. 135 (2015), 1705–1707.
41. 41 Bohnekamp, J., et al. A Drosophila model of Epidermolysis bullosa simplex. J. Invest. Dermatol. 135 (2015), 2031–2039.
42. 42 El Ghalbzouri, A., et al. Recessive Epidermolysis bullosa simplex phenotype reproduced in vitro. Am. J. Pathol. 163 (2003), 1771–1779.
43. 43 Chamcheu, J.C., et al. Keratin gene mutations in disorders of human skin and its appendages. Arch. Biochem. Biophys. 508 (2011), 123–137.
44. 44 Chamcheu, J.C., et al. Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. Exp. Dermatol. 21 (2012), 481–489.
45. 45 Koga, H., et al. Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris. Expert Opin. Ther. Targets 17 (2013), 293–306.
46. 46 Cogan, J., et al. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol. Ther. 22 (2014), 1741–1752.
47. 47 Martin, G., et al. Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. Lab. Invest. 92 (2012), 1058–1070.
48. 48 Jean, J., et al. Development of an in vitro psoriatic skin model by tissue engineering. J. Dermatol. Sci. 53 (2009), 19–25.
49. 49 Hedrick, M.N., et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J. Clin. Invest. 119 (2009), 2317–2329.
50. 50 Flutter, B., Nestle, F.O., TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur. J. Immunol. 43 (2013), 3138–3146.
51. 51 Tjabringa, G., et al. Development and validation of human psoriatic skin equivalents. Am. J. Pathol. 173 (2008), 815–823.
52. 52 Barker, C.L., et al. The development and characterization of an in vitro model of psoriasis. J. Invest. Dermatol. 123 (2004), 892–901.
53. 53 van den Bogaard, E.H., et al. Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. J. Invest. Dermatol. 134 (2014), 719–727.
54. 54 Lo, J.A., Fisher, D.E., The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 346 (2014), 945–949.
55. 55 Reichrath, J., Sunlight, Vitamin D and Skin Cancer. 2008, Landes Bioscience/Springer Science+Business Media LLC.
56. 56 Karachaliou, N., et al. Melanoma: oncogenic drivers and the immune system. Ann. Transl. Med., 3, 2015, 265.
57. 57 van de Ven, R., et al. Dendritic cell plasticity in tumor-conditioned skin: CD14(+) cells at the cross-roads of immune activation and suppression. Front. Immunol., 4, 2013, 403.
58. 58 Medler, T.R., Coussens, L.M., Duality of the immune response in cancer: lessons learned from skin. J. Invest. Dermatol. 134 (2014), E23–E28.
59. 59 Yu, S.H., et al. The immune system and skin cancer. Adv. Exp. Med. Biol. 810 (2014), 182–191.
60. 60 van der Weyden, L., et al. Cross-species models of human melanoma. J. Pathol. 238 (2016), 152–165.
61. 61 Kasper, M., et al. Basal cell carcinoma – molecular biology and potential new therapies. J. Clin. Invest. 122 (2012), 455–463.
62. 62 Commandeur, S., Organotypic In Vitro Models of Human Cutaneous Squamous Cell Carcinoma. PhD Thesis, 2013, Leiden University.
63. 63 Berking, C., Herlyn, M., Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol. Histopathol. 16 (2001), 669–674.
64. 64 Zhang, T., et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur. J. Immunol. 36 (2006), 457–467.
65. 65 Linde, N., et al. Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLoS ONE, 7, 2012, e40058.
66. 66 Leight, J.L., et al. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 5366–5371.
67. 67 Vorsmann, H., et al. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis., 4, 2013, e719.
68. 68 Commandeur, S., et al. Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma. Cancer Sci. 103 (2012), 2120–2126.
69. 69 Elamin, I., et al. Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol. Alp. Pannonica Adriat. 17 (2008), 55–59.
70. 70 Commandeur, S., et al. An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp. Dermatol. 18 (2009), 849–856.
71. 71 Mattei, F., et al. A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. J. Immunotoxicol. 11 (2014), 337–346.
72. 72 Martin, S.F., Immunological mechanisms in allergic contact dermatitis. Curr. Opin. Allergy Clin. Immunol. 15 (2015), 124–130.
73. 73 Martin, S.F., New concepts in cutaneous allergy. Contact Dermatitis 72 (2015), 2–10.
74. 74 Corsini, E., et al. Safety evaluation of cosmetic ingredients: in vitro opportunities for the identification of contact allergens. Cosmetics 1 (2014), 61–74.
75. 75 Basketter, D.A., et al. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing – t4 report*. ALTEX 29 (2012), 3–91.
76. 76 Holmes, A., et al. Assessing drug safety in human tissues – what are the barriers?. Nat. Rev. Drug Discov. 14 (2015), 585–587.
77. 77 Reisinger, K., et al. Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. Toxicol. In Vitro 29 (2015), 259–270.
78. 78 Jaworska, J.S., et al. Bayesian integrated testing strategy (ITS) for skin sensitization potency assessment: a decision support system for quantitative weight of evidence and adaptive testing strategy. Arch. Toxicol. 89 (2015), 2355–2383.
79. 79 Nukada, Y., et al. Data integration of non-animal tests for the development of a test battery to predict the skin sensitizing potential and potency of chemicals. Toxicol. In Vitro 27 (2013), 609–618.
80. 80 Urbisch, D., et al. Assessing skin sensitization hazard in mice and men using non-animal test methods. Regul. Toxicol. Pharmacol. 71 (2015), 337–351.
81. 81 Gibbs, S., et al. An epidermal equivalent assay for identification and ranking potency of contact sensitizers. Toxicol. Appl. Pharmacol. 272 (2013), 529–541.
82. 82 Kosten, I.J., et al. MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. Toxicol. Appl. Pharmacol. 287 (2015), 35–42.
83. 83 Esch, E.W., et al. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14 (2015), 248–260.
84. 84 Giese, C., Marx, U., Human immunity in vitro – solving immunogenicity and more. Adv. Drug Deliv. Rev. 69–70 (2014), 103–122.
85. 85 Bhatia, S.N., Ingber, D.E., Microfluidic organs-on-chips. Nat. Biotechnol. 32 (2014), 760–772.
86. 86 Capulli, A.K., et al. Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip 14 (2014), 3181–3186.
87. 87 Ramadan, Q., Gijs, M.A., In vitro micro-physiological models for translational immunology. Lab Chip 15 (2015), 614–636.
88. 88 Benam, K.H., et al. Engineered in vitro disease models. Annu. Rev. Pathol. 10 (2015), 195–262.
89. 89 Huh, D., et al. Reconstituting organ-level lung functions on a chip. Science 328 (2010), 1662–1668.
90. 90 Han, S., et al. A versatile assay for monitoring in vivo-like transendothelial migration of neutrophils. Lab Chip 12 (2012), 3861–3865.
91. 91 Wagner, I., et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 13 (2013), 3538–3547.
92. 92 Atac, B., et al. Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. Lab Chip 13 (2013), 3555–3561.
93. 93 Maschmeyer, I., et al. Chip-based human liver-intestine and liver-skin co-cultures—a first step toward systemic repeated dose substance testing in vitro. Eur. J. Pharm. Biopharm. 95 (2015), 77–87.
94. 94 Abaci, H.E., et al. Pumpless microfluidic platform for drug testing on human skin equivalents. Lab Chip 15 (2015), 882–888.
95. 95 Sellgren, K.L., et al. A biomimetic multicellular model of the airways using primary human cells. Lab Chip 14 (2014), 3349–3358.
96. 96 Griep, L.M., et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood–brain barrier function. Biomed. Microdevices 15 (2013), 145–150.
97. 97 Jeon, J.S., et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc. Natl. Acad. Sci. U. S. A., 112, 2015, E818.
98. 98 Giese, C., et al. Immunological substance testing on human lymphatic micro-organoids in vitro. J. Biotechnol. 148 (2010), 38–45.
99. 99 Torisawa, Y.S., et al. Bone marrow-on-a-chip replicates hematopoietic niche physiology in vitro. Nat. Methods 11 (2014), 663–669.
100. 100 Chen, P., et al. Label-free cytokine micro- and nano-biosensing towards personalized medicine of systemic inflammatory disorders. Adv. Drug Deliv. Rev. 95 (2015), 90–103.
101. 101 Giri, S., Bader, A., A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. Drug Discov. Today 20 (2015), 37–49.
102. 102 Inoue, H., et al. iPS cells: a game changer for future medicine. EMBO J. 33 (2014), 409–417.
103. 103 Ohta, S., et al. The potential of using induced pluripotent stem cells in skin diseases. Schatten, H., (eds.) Cell and Molecular Biology and Imaging of Stem Cells, 2014, John Wiley & Sons, 223–245.
104. 104 Gledhill, K., et al. Melanin transfer in human 3D skin equivalents generated exclusively from induced pluripotent stem cells. PLOS ONE, 10, 2015, e0136713.
105. 105 Moulin, V., Reconstitution of skin fibrosis development using a tissue engineering approach. Has, C., Sitaru, C., (eds.) Molecular Dermatology, vol. 961, 2013, Humana Press, 287–303.
106. 106 Warrington, K.J., et al. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res. Ther., 8, 2006, R136.
107. 107 De Palma, R., et al. Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role?. Rheumatology 49 (2010), 1257–1266.
108. 108 Wu, J., et al. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol. Med. Rep. 7 (2013), 237–241.
109. 109 Bondanza, S., et al. Keratinocyte cultures from involved skin in vitiligo patients show an impaired in vitro behaviour. Pigment Cell Res. 20 (2007), 288–300.
110. 110 Auriemma, M., et al. Alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. J. Invest. Dermatol. 132 (2012), 1814–1824.
111. 111 Zhang, T., et al. CXC chemokine ligand 12 (stromal cell-derived factor 1) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J. Invest. Dermatol. 174 (2005), 5856–5863.
112. 112 Hill, D.S., et al. A novel fully humanized 3D skin equivalent to model early melanoma invasion. Mol. Cancer Ther. 14 (2015), 2665–2673.
113. 113 Berning, M., et al. Three-dimensional in vitro skin and skin cancer models based on human fibroblast-derived matrix. Tissue Eng. Part C Methods 21 (2015), 958–970.
114. 114 Natsch, A., Emter, R., Reporter cell lines for skin sensitization testing. Arch. Toxicol. 89 (2015), 1645–1668.
115. 115 Kimura, Y., et al. Optimization of the IL-8 Luc assay as an in vitro test for skin sensitization. Toxicol. In Vitro 29 (2015), 1816–1830.
116. 116 Albrekt, A.S., et al. Skin sensitizers differentially regulate signaling pathways in MUTZ-3 cells in relation to their individual potency. BMC Pharmacol. Toxicol. 15 (2014), 1–13.
117. 117 Cottrez, F., et al. Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay. Toxicol. In Vitro 29 (2015), 787–802.
118. 118 Saito, K., et al. Development of a new in vitro skin sensitization assay (epidermal sensitization assay; EpiSensA) using reconstructed human epidermis. Toxicol. In Vitro 27 (2013), 2213–2224.